10-Q · May 11, 2026
Bicara Therapeutics (BCAX) reported its Q1 2026 financial results, showing continued challenges with net losses increasing to $56.2 million compared to $36.8 million in Q1 2025. Operating expenses surged, primarily…
Earnings analysis · 10-Q
BCAX earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Bicara remains a clinical-stage, pre-revenue biotech with diluted EPS of $(0.82) and a sharply higher net loss of $55.4 million in the second quarter. The $497.3 million cash, cash equivalents and marketable securities…
Read full summary
Bicara remains a clinical-stage, pre-revenue biotech with diluted EPS of $(0.82) and a sharply higher net loss of $55.4 million in the second quarter. The $497.3 million cash, cash equivalents and marketable securities balance supports operations into the first half of 2029, and the company continues advancing ficerafusp alfa and FORTIFI-HN01. However, widening losses, patent litigation, China-linked manufacturing exposure and significant executive transitions temper the otherwise supportive cash-runway and clinical-execution outlook.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.82
What stood out
-
Cash runway extends into 1H 2029
Cash, cash equivalents and marketable securities totaled $497.3 million as of June 30, 2026. Management believes this is sufficient to fund operating expenses and capital expenditure requirements into the first half of 2029.
-
Strong access to equity capital
The company raised approximately $161.8 million of net proceeds in the February 2026 Offering and an additional $29.5 million of aggregate net proceeds through its ATM Program as of June 30, 2026.
-
Clinical program remains active
Bicara reported diluted EPS of $(0.82), compared with the $(0.81) consensus estimate. The company continues to advance ficerafusp alfa, including the Phase 2/3 FORTIFI-HN01 pivotal trial.
-
No reported control deficiencies
The company’s disclosure controls and procedures were assessed as effective at the reasonable assurance level as of June 30, 2026, and there were no material changes in internal control over financial reporting during the quarter.
What to watch
-
Losses are widening materially
Net loss increased to $55.4 million for the three months ended June 30, 2026, from $27.4 million in the prior-year period; six-month net loss was $111.6 million versus $64.2 million. Management expects significant losses to continue and increase as development advances.
-
CFO transition adds execution risk
The CFO transition is effective August 12, 2026: Ivan Hyep will receive 12 months of salary continuation at a final base pay rate of $500,000, while Jennifer Larson becomes CFO with a $520,000 base salary and a 285,000-share stock option award.
-
CEO succession creates uncertainty
The CEO transition introduces multiple leadership changes: Claire Mazumdar will begin parental leave on September 1, 2026, Ryan Cohlhepp becomes Interim CEO on that date and CEO on January 1, 2027, and Tanya Green is scheduled to become COO on January 1, 2027.
-
Patent litigation remains material
The company is defending Y-Trap litigation involving inventorship and other claims related to patents licensed to Bicara; the court denied the motion to dismiss on September 30, 2025 and discovery remains ongoing. Separately, the PTAB instituted a post-grant review on July 15, 2026, with a final written decision anticipated by July 14, 2027.
-
China-linked manufacturing exposure
The company relies primarily on WuXi Biologics (Hong Kong) Limited for production needed to complete ongoing clinical trials and has no long-term supply agreements in place. The filing also identifies BIOSECURE Act implementation, with substantive prohibitions not expected before 2027, as a potential threat to Chinese biotech relationships and supply continuity.
-
Additional financing may dilute holders
Potential dilution remains significant: the company had 2,200,000 pre-funded warrants outstanding as of the filing date, and the ATM Program permits sales of up to $150.0 million of common stock. The company also has a $400.0 million shelf registration covering common stock, preferred stock, debt securities, warrants and units.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management states that $497.3 million of cash, cash equivalents and marketable securities is expected to fund operating expenses and capital expenditures into the first half of 2029.
Earlier filings 4
10-K · March 30, 2026
Bicara (BCAX) remains a clinical-stage biotech focused on ficerafusp alfa, a bifunctional EGFR-directed antibody with a TGF-β ligand trap. The company has advanced to a global Phase 2/3 FORTIFI-HN01 trial (1500 mg QW…
10-Q · November 10, 2025
Bicara reported a Q3 net loss of $(36,330) thousand (EPS $(0.67)), driven by a sustained R&D ramp and higher operating expenses. Cash and investments remain sizable at approximately $407.6 million ($171,673 cash +…
10-Q · August 12, 2025
Bicara reported no revenue and a wider Q2 net loss of $(27,388) (EPS $(0.50)) versus $(17,049) in Q2 2024; six‑month net loss was $(64,234) (EPS $(1.18)) compared with $(29,557) a year ago. Operating expenses increased…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.